Study Evaluating Bifeprunox in Bipolar Depression

• Status: Completed
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Collaborator: Solvay Pharmaceuticals

Criteria

Inclusion Criteria:

• Diagnosis of bipolar disorder

• Experiencing a depressive episode